Birth defects of diethylstilbestrol

Diethylstilbestrol (DES), a synthetic nonsteroidal estrogen which was previously used clinically to support pregnancy, has been linked to a variety of long-term adverse effects in women who were treated with it during pregnancy and in their offspring.[1]

First generation

An estimated 3 million pregnant women in the USA were prescribed DES from 1941 through 1971.[2][3] DES was also widely prescribed to women in Canada, the UK, Europe, Australia, and New Zealand during a similar period. Women who were prescribed DES during pregnancy have been shown to have a modestly increased risk of breast cancer and breast cancer mortality.[4]

Second generation

DES daughters

DES gained notoriety when it was shown to cause a rare vaginal tumor in girls and young women who had been exposed to this drug in utero. In 1971, the New England Journal of Medicine published a report showing that seven of eight girls and young women (ages 14 to 22) who had been diagnosed with vaginal clear cell adenocarcinoma had been exposed prenatally to DES.[5] Subsequent studies have shown an approximate 40-fold increased risk of vaginal/cervical clear cell adenocarcinoma in women exposed in utero to DES. As a consequence of this evidence, DES is considered an established human carcinogen. DES was one of the first transplacental carcinogens discovered in humans, meaning a toxin could cross the placenta and harm the fetus. It had originally been believed that the placenta protected the developing fetus but it is now known that is not true. Daughters exposed to DES in utero may also have an increased risk of moderate to severe cervical squamous cell dysplasia and an increased risk of breast cancer.[6]

In addition to its carcinogenic properties, DES is a known teratogen, an agent capable of causing malformations in daughters and sons who were exposed in utero. DES-exposed daughters are at an increased risk of abnormalities of the reproductive tract, including vaginal epithelial changes such as vaginal adenosis (which means a type of cell normally found in the uterus, columnar cells, are also present in the vagina), an increased cervical transformation zone, and uterine abnormalities, such as T-shaped uterus. These anomalies contribute to an increased risk of infertility and adverse pregnancy outcomes in prenatally DES-exposed daughters. The most recent published research on DES daughters' adverse health outcomes documented by the U.S. National Cancer Institute (NCI) appears in the October 6, 2011 issue of the New England Journal of Medicine under the authorship of RN Hoover et al., and lists these adverse effects and risk factors: Cumulative risks in women exposed to DES, as compared with those not exposed, were as follows: for infertility, 33.3% vs. 15.5%; spontaneous abortion, 50.3% vs. 38.6%; preterm delivery, 53.3% vs. 17.8%; loss of second-trimester pregnancy, 16.4% vs. 1.7%; ectopic pregnancy, 14.6% vs. 2.9%; preeclampsia, 26.4% vs. 13.7%; stillbirth, 8.9% vs. 2.6%; early menopause, 5.1% vs. 1.7%; grade 2 or higher cervical intraepithelial neoplasia, 6.9% vs. 3.4%; and breast cancer at 40 years of age or older, 3.9% vs. 2.2%.[7] Daughters with prenatal exposure to DES may also have an increased risk of uterine fibroids, and incompetent cervix in adulthood.[8]

Studies of DES daughters have not found a link between in utero exposure to DES and autoimmune diseases.[9]

In an animal model designed to study environmental estrogens, DES turned out to be an obesogen capable of causing adult weight gain in female mice which had been exposed to DES during neonatal development. The excess weight gain was not apparent at birth or in infancy, but occurred in adulthood.[10][11]

DES sons

Initially, fewer studies documented risks of prenatal exposure to DES on males (referred to as "DES sons"). In the 1970s and early 1980s, studies published on prenatally DES-exposed males investigated increased risk of testicular cancer, infertility and urogenital abnormalities in development, such as cryptorchidism and hypospadias.[12][13] Research published in the U.S. by Palmer et al. in 2009 further confirmed evidence of these findings.[14] Additional research published in Finland in 2012 has further confirmed an increased risk of cryptorchidism among males exposed prenatally to DES.[15]

The U.S. Centers for Disease Control (CDC) has acknowledged the link between DES exposure and noncancerous epididymal cysts.[16]

The American Association of Clinical Endocrinologists (AACE) has documented that prenatal DES exposure in males is positively linked to a condition known as hypogonadism (low testosterone levels) that may require treatment with testosterone replacement therapy.[17]

Sexual differentiation

Research investigating the possible behavioral and psychosexual effects of prenatal DES exposure in human males occurred as early as 1973.[18] This research has centered on a long-standing question of whether prenatal exposure to DES in offspring of mothers who were prescribed DES may have included sexual orientation and gender-related behavioral effects and physical intersex conditions.[19] Kaplan published the first-known medical study (1959) of intersex condition in a male prenatally-exposed to DES.[20]

There is some evidence linking prenatal hormonal influences on sexual orientation, gender identity and transgender development, but this is an area of behavioral research that remains controversial.[21][22][23][24] Several published studies in the medical literature have examined the hypothesis that prenatal exposure to estrogens (including DES) may cause significant developmental impact on sexual differentiation of the brain, and on subsequent behavioral and gender identity development in exposed males and females. One of the leading investigators of this area of research is June Reinisch, former director of the Kinsey Institute for Research in Sex, Gender, and Reproduction.[18][25] Reinisch cited several cases of "male feminization" among prenatally DES-exposed males.

An Internet survey reported a high rate of transgender and intersex identity in people assigned male at birth participating in an online support forum for DES sons.[26][27][28] Of 500 respondents, about 32% identified as transgender, transsexual, gender dysphoric, or intersex (90, 48, 17, and 3, respectively).[26][28][27] The first real study on transgender identity in people assigned male at birth who were prenatally exposed to DES was published in 2020 and found a very low incidence of transgenderism (2 in about 930 or around 0.2%).[29] It wasn't possible to determine whether the incidence was higher than in controls due to the small number of cases, but the findings did indicate in any case that the influence of prenatal DES exposure on likelihood of being transgender would be only small at most.[29]

DES Daughters and Sons study

A study conducted by the US National Cancer Institute, which assessed about 5,600 women and 2,600 men who had documented prenatal exposure to DES, called "DES Daughters" and "DES Sons", respectively, found that "DES Daughters were just as likely as unexposed women to be left-handed. DES Sons were slightly more likely to be left-handed than unexposed men (14% vs. 11%, respectively).[30] The researchers found no association between DES exposure and reported mental illness in DES Daughters, although the authors cautioned that this aspect may be under-represented due to the nature of self-reported data. In addition, no association was found between DES exposure and anorexia or bulimia."[31]

Psychological anomalies

Most of the initial research documenting the psychological effects of prenatal DES exposure was poorly conducted, often by mail card. Despite that, some more carefully conducted studies show a clear link to depression,[32][33] and a more recent French study asserts that there was an 83% increase in psychological disorders for offspring that were prenatally exposed to DES.[34]

Third generation

Current research also looks at DES in the third generation. These are the grandchildren of women who were given DES during pregnancy and whose mother or father was therefore exposed to DES in utero. Studies of the third generation are important because DES might be associated with epigenetic changes, which involve changes to the way genes behave (not involving the DNA itself) that may be heritable from one generation to another. If epigenetic changes occur and are heritable, studies of the DES-exposed third generation have implications for the influence of environmental endocrine disruptors on human health and evolution.

Recent studies from the US National Cancer Institute (NCI) show that the daughters of women who were exposed in utero to DES may be less likely than the unexposed to have regular menstrual periods.[35] A possible increased risk of infertility in the older, third generation daughters was also noted. The NCI study provides limited evidence of an increased risk of birth defects in the sons or daughters of women who were exposed prenatally to DES. An increased risk of ovarian cancer in the daughters of women exposed in utero was observed, but it was based on three cases of almost 800, so the finding is considered preliminary and requires further study.

Some evidence suggests the sons of prenatally DES-exposed women might have an increased risk of hypospadias,[36][37] but other studies suggest the increase in risk might not be as great as once thought.[38]

gollark: (same drop too)
gollark: Missed a paper and aeon in the same biome!
gollark: Does anyone know, really?
gollark: If only I actually got that xenowyrm yesterday.
gollark: So someone probably has one and offered.

References
  1. Bamigboye AA, Morris J (2003). "Oestrogen supplementation, mainly diethylstilbestrol, for preventing miscarriages and other adverse pregnancy outcomes". Cochrane Database Syst Rev (3): CD004353. doi:10.1002/14651858.CD004353. PMID 12918007.
  2. "Problems in Research: Regulations—The Diethylstilbestrol Tragedy". The Medical Bag. 12 April 2013. Retrieved 29 April 2014.
  3. Hammes B, Laitman CJ (Jan–Feb 2003). "Diethylstilbestrol (DES) update: recommendations for the identification and management of DES-exposed individuals". Journal of Midwifery & Women's Health. 48 (1): 19–29. doi:10.1016/s1526-9523(02)00370-7. PMID 12589302.
  4. Titus-Ernstoff L, Hatch EE, Hoover RN, Palmer J, Greenberg ER, Ricker W, Kaufman R, Noller K, Herbst A, Colton T, Hartge P (January 2001). "Longterm cancer risk in women given diethystilbestrol (DES) in pregnancy". British Journal of Cancer. 84 (1): 126–133. doi:10.1054/bjoc.2000.1521. PMC 2363605. PMID 11139327.
  5. Herbst AL, Ulfelder H, Poskanzer DC (April 1971). "Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women". The New England Journal of Medicine. 284 (15): 878–81. doi:10.1056/NEJM197104222841604. PMID 5549830.
  6. Troisi R, Hatch EE, Titus-Ernstoff L, Hyer M, Palmer JR, Robboy SJ, Strohsnitter WC, Kaufman R, Herbst AL, Hoover RN (July 2007). "Cancer risk in women prenatally exposed to diethylstilbestrol". International Journal of Cancer. 121 (2): 356–60. doi:10.1002/ijc.22631. PMID 17390375.
  7. Hoover RN, Hyer M, Pfeiffer RM, Adam E, Bond B, Cheville AL, Colton T, Hartge P, Hatch EE, Herbst AL, Karlan BY, Kaufman R, Noller KL, Palmer JR, Robboy SJ, Saal RC, Strohsnitter W, Titus-Ernstoff L, Troisi R (October 2011). "Adverse health outcomes in women exposed in utero to diethylstilbestrol". The New England Journal of Medicine. 365 (14): 1304–14. doi:10.1056/NEJMoa1013961. PMID 21991952.
  8. Office of Research on Women’s Health, NIH, DHHS (March 2006). "Status of Research on Uterine Fibroids (leiomyomata uteri) at the National Institutes of Health" (PDF). United States National Institutes of Health. Archived from the original (PDF) on 2010-05-27. Retrieved 2018-07-21.CS1 maint: multiple names: authors list (link)
  9. Strohsnitter WC, Noller KL, Troisi R, Robboy SJ, Hatch EE, Titus-Ernstoff L, Kaufman RH, Palmer JR, Anderson D, Hoover RN (October 2010). "Autoimmune disease incidence among women prenatally exposed to diethylstilbestrol". The Journal of Rheumatology. 37 (10): 2167–73. doi:10.3899/jrheum.091092. PMC 2988471. PMID 20634240.
  10. Newbold RR, Padilla-Banks E, Snyder RJ, Jefferson WN (July 2007). "Perinatal exposure to environmental estrogens and the development of obesity". Molecular Nutrition & Food Research. 51 (7): 912–7. doi:10.1002/mnfr.200600259. PMID 17604389.
  11. Newbold RR, Padilla-Banks E, Snyder RJ, Phillips TM, Jefferson WN (2007). "Developmental exposure to endocrine disruptors and the obesity epidemic". Reproductive Toxicology. 23 (3): 290–6. doi:10.1016/j.reprotox.2006.12.010. PMC 1931509. PMID 17321108.
  12. Henderson BE, Benton B, Cosgrove M, Baptista J, Aldrich J, Townsend D, Hart W, Mack TM (October 1976). "Urogenital tract abnormalities in sons of women treated with diethylstilbestrol". Pediatrics. 58 (4): 505–7. PMID 972792.
  13. Gill WB, Schumacher GF, Bibbo M, Straus FH, Schoenberg HW (July 1979). "Association of diethylstilbestrol exposure in utero with cryptorchidism, testicular hypoplasia and semen abnormalities". The Journal of Urology. 122 (1): 36–9. doi:10.1016/s0022-5347(17)56240-0. PMID 37351.
  14. Palmer JR, Herbst AL, Noller KL, Boggs DA, Troisi R, Titus-Ernstoff L, Hatch EE, Wise LA, Strohsnitter WC, Hoover RN (August 2009). "Urogenital abnormalities in men exposed to diethylstilbestrol in utero: a cohort study". Environmental Health. 8: 37. doi:10.1186/1476-069X-8-37. PMC 2739506. PMID 19689815.
  15. Virtanen HE, Adamsson A (May 2012). "Cryptorchidism and endocrine disrupting chemicals". Molecular and Cellular Endocrinology. 355 (2): 208–20. doi:10.1016/j.mce.2011.11.015. PMID 22127307.
  16. "Known Health Effects for DES Sons". United States Department of Health and Human Services: Centers for Disease Control and Prevention. Retrieved 2011-06-30.
  17. "American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult-Male Patients--2002 Update" (PDF). American Association of Clinical Endocrinologists. Archived from the original (PDF) on 2017-08-09. Retrieved 2018-07-21.
  18. Yalom ID, Green R, Fisk N (April 1973). "Prenatal exposure to female hormones. Effect on psychosexual development in boys". Archives of General Psychiatry. 28 (4): 554–61. doi:10.1001/archpsyc.1973.01750340080013. PMID 4734959.
  19. Hines M (April 2011). "Prenatal endocrine influences on sexual orientation and on sexually differentiated childhood behavior". Frontiers in Neuroendocrinology. 32 (2): 170–82. doi:10.1016/j.yfrne.2011.02.006. PMC 3296090. PMID 21333673.
  20. Kaplan NM (September 1959). "Male pseudohermaphrodism: report of a case, with observations on pathogenesis". The New England Journal of Medicine. 261 (13): 641–4. doi:10.1056/NEJM195909242611303. PMID 14404413.
  21. Michel A, Mormont C, Legros JJ (October 2001). "A psycho-endocrinological overview of transsexualism". European Journal of Endocrinology. 145 (4): 365–76. doi:10.1530/eje.0.1450365. PMID 11580991.
  22. Selvaggi G, Ceulemans P, De Cuypere G, VanLanduyt K, Blondeel P, Hamdi M, Bowman C, Monstrey S (November 2005). "Gender identity disorder: general overview and surgical treatment for vaginoplasty in male-to-female transsexuals" (PDF). Plastic and Reconstructive Surgery. 116 (6): 135e–145e. doi:10.1097/01.prs.0000185999.71439.06. PMID 16267416. Archived from the original (PDF) on 2013-10-14. Retrieved 2018-07-21.
  23. Dingfelder S (2004). "Gender Bender: New Research Suggests Genes and Prenatal Hormones Could Have More Sway in Gender Identity than Previously Thought". APA Monitor on Psychology. 35 (4): 48.
  24. Hood E (October 2005). "Are EDCs blurring issues of gender?". Environmental Health Perspectives. 113 (10): A670–7. doi:10.1289/ehp.113-a670. PMC 1281309. PMID 16203228.
  25. Reinisch JM, Ziemba-Davis M, Sanders SA (1991). "Hormonal contributions to sexually dimorphic behavioral development in humans". Psychoneuroendocrinology. 16 (1–3): 213–78. doi:10.1016/0306-4530(91)90080-D. PMID 1961841.
  26. Ettner, Randi (2015). "Etiopathogenetic Hypotheses of Transsexualism". In Carlo Trombetta; Giovanni Liguori; Michele Bertolotto (eds.). Management of Gender Dysphoria. pp. 47–53. doi:10.1007/978-88-470-5696-1_6. ISBN 978-88-470-5695-4. Diethylstilbestrol (DES), the most studied endocrine disruptor, has been implicated in numerous health problems in female offspring of exposed women [46]. Curiously, few studies have examined the impact on male offspring, the DES sons. An online forum, DES Sons International, conducted a survey of members. Of 500 respondents, 90 members indicated they were transsexual; 48 described themselves as transgender; 17 identified themselves as “gender dysphoric”; and 3 identified themselves as “intersex.” By 2004, more than 130 individuals had joined a forum called “DES Trans” [44]. Clearly, the prevalence of gender dysphoria in persons exposed to DES warrants further study.
  27. Ettner, Randi (2020). "Etiology of Gender Dysphoria". In Loren S. Schechter (ed.). Gender Confirmation Surgery: Principles and Techniques for an Emerging Field. pp. 21–28. doi:10.1007/978-3-030-29093-1_2. ISBN 978-3-030-29092-4. Diethylstilbestrol (DES), the most widely studied endocrine disruptor, has been implicated in numerous health problems in female offspring of exposed women [34]. Few studies, however, have examined its impact on male offspring. DES Sons International, an online forum, surveyed 500 member respondents, 90 of whom identified as “transsexual,” 48 described themselves as “transgender,” 17 identified as “gender dysphoric,” and 3 as “intersex” [35].
  28. Randi Ettner; Antonio Guillamon (20 May 2016). "Theories of the Etiology of Transgender Identity". In Randi Ettner; Stan Monstrey; Eli Coleman (eds.). Principles of Transgender Medicine and Surgery. Routledge. pp. 3–15. ISBN 978-1-317-51460-2. Diethystilbestrol (DES), the most widely studied endocrine disruptor, has been implicated in numerous health problems in female offspring of exposed women (Langston, 2010). Few studies, however, have examined its impact on male offspring. DES Sons International, an online forum, reported that in a survey of 500 member respondents, 90 identified as "transsexual"; 48 described themselves as "transgender"; 17 identified as "gender-dysphoric"; and three as "intersex" (Kerlin, 2004).
  29. Troisi R, Palmer JR, Hatch EE, Strohsnitter WC, Huo D, Hyer M, Fredriksen-Goldsen KI, Hoover R, Titus L (February 2020). "Gender Identity and Sexual Orientation Identity in Women and Men Prenatally Exposed to Diethylstilbestrol". Arch Sex Behav. 49 (2): 447–454. doi:10.1007/s10508-020-01637-7. PMC 7031187. PMID 31975033.
  30. Titus-Ernstoff, Linda (March 2003). "Psychosexual characteristics of men and women exposed prenatally to diethylstilbestrol". Epidemiology. 14 (2): 155–160. doi:10.1097/01.EDE.0000039059.38824.B2. PMID 12606880.
  31. "Recent DES Research: Psychosexual Characteristics of Men and Women Exposed Prenatally to Diethylstilbestrol". CDC. Retrieved 16 May 2017.
  32. Pillard RC, Rosen LR, Meyer-Bahlburg H, Weinrich JD, Feldman JF, Gruen R, Ehrhardt AA (1993). "Psychopathology and social functioning in men prenatally exposed to diethylstilbestrol (DES)". Psychosomatic Medicine. 55 (6): 485–91. doi:10.1097/00006842-199311000-00003. PMID 8310108.
  33. O'Reilly EJ, Mirzaei F, Forman MR, Ascherio A (April 2010). "Diethylstilbestrol exposure in utero and depression in women". American Journal of Epidemiology. 171 (8): 876–82. doi:10.1093/aje/kwq023. PMC 2877444. PMID 20332145.
  34. Soyer-Gobillard MO, Paris F, Gaspari L, Courtet P, Sultan C (2016). "Association between fetal DES-exposure and psychiatric disorders in adolescence/adulthood: evidence from a French cohort of 1002 prenatally exposed children". Gynecological Endocrinology. 32 (1): 25–9. doi:10.3109/09513590.2015.1063604. PMID 26172930.
  35. Titus-Ernstoff L, Troisi R, Hatch EE, Wise LA, Palmer J, Hyer M, Kaufman R, Adam E, Strohsnitter W, Noller K, Herbst AL, Gibson-Chambers J, Hartge P, Hoover RN (August 2006). "Menstrual and reproductive characteristics of women whose mothers were exposed in utero to diethylstilbestrol (DES)". International Journal of Epidemiology. 35 (4): 862–8. doi:10.1093/ije/dyl106. PMID 16723367.
  36. Klip H, Verloop J, van Gool JD, Koster ME, Burger CW, van Leeuwen FE (March 2002). "Hypospadias in sons of women exposed to diethylstilbestrol in utero: a cohort study". Lancet. 359 (9312): 1102–7. doi:10.1016/S0140-6736(02)08152-7. PMID 11943257.
  37. Kalfa N, Paris F, Soyer-Gobillard MO, Daures JP, Sultan C (June 2011). "Prevalence of hypospadias in grandsons of women exposed to diethylstilbestrol during pregnancy: a multigenerational national cohort study". Fertility and Sterility. 95 (8): 2574–7. doi:10.1016/j.fertnstert.2011.02.047. PMID 21458804.
  38. Brouwers MM, Feitz WF, Roelofs LA, Kiemeney LA, de Gier RP, Roeleveld N (March 2006). "Hypospadias: a transgenerational effect of diethylstilbestrol?". Human Reproduction. 21 (3): 666–9. doi:10.1093/humrep/dei398. PMID 16293648.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.